Goldman Sachs Remains Bullish on AstraZeneca (AZN)

AstraZeneca PLC (NASDAQ:AZN) is one of the best UK stocks to buy right now. On September 1, Goldman Sachs analyst Rajan Sharma maintained a bullish stance on AstraZeneca PLC (NASDAQ:AZN), giving the stock a Buy rating with a $97 price target.

The analyst based the rating on the company’s growth potential and solid market position, stating that AstraZeneca PLC (NASDAQ:AZN) has a robust pipeline of innovative drugs, especially in the cardiovascular and oncology segments, positioning the company for sustained revenue growth.

Sharma added that strategic acquisitions and partnerships have allowed AstraZeneca PLC (NASDAQ:AZN) to boost its research capabilities and expand its product offerings, giving the company a competitive edge in the pharmaceutical industry.

AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians. AstraZeneca PLC (NASDAQ:AZN) distributes its products and services through local representative offices and distributors.

While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.